We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Diagnostic Test for Brain Tumors to Reduce Need for Invasive Surgical Biopsy

By LabMedica International staff writers
Posted on 20 Jun 2024

Most brain and spinal cord tumors are diagnosed in the hospital setting, often after patients exhibit rapidly progressing deficits. More...

Given the urgency, the traditional delays and risks associated with neurosurgical biopsies can hinder prompt diagnosis and treatment of central nervous system (CNS) tumors. Researchers have now developed a rapid genotyping test for patients presenting with CNS lesions, which has eliminated the need for invasive surgical biopsies in seven cases, reducing the time to diagnosis from 10 days to just 2.

The rapid genotyping test developed by a collaborative team of neurosurgeons, oncologists, and pathologists at Mass General Brigham (Somerville, MA, USA) identifies genetic markers of various CNS tumors from cerebrospinal fluid (CSF), gathered during a lumbar procedure. This test not only speeds up the diagnosis but also avoids the need for more invasive brain biopsies in some cases. The team utilized a method called TetRS (Targeted Rapid Sequencing) in a study involving 70 patients with newly identified CNS lesions of unknown origin. The development of TetRS dates back almost a decade when researchers identified a few genes frequently mutated in specific brain cancers. By 2015, they demonstrated that these genetic mutations could be detected in tissue samples removed during surgery, and by 2021, they successfully applied TetRS to cerebrospinal fluid.

In their latest study, the researchers tested TetRS in real-world situations where patients might arrive in the Emergency Department with an abnormal lesion that could be either from a tumor or benign. The study aimed to verify that TetRS could expedite accurate diagnoses without the risk of false positives. TetRS was specifically designed to identify genetic signatures indicative of brain cancer, focusing on mutations in genes such as MYD88, TERT promoter, IDH1, IDH2, BRAF, and H3F3A. Of the 70 patients evaluated, 33 were eventually diagnosed with neoplasms. TetRS alone diagnosed six of these patients, and when combined with traditional diagnostic approaches, it identified an additional eight, achieving a sensitivity of 42%. For the 37 patients not diagnosed with neoplasms, TetRS reported no false positives, demonstrating a specificity of 100%. 

The use of this rapid genotyping test not only eliminated the need for surgical biopsies in seven cases but also significantly reduced the average time to treatment initiation, from 12 days to just 3 days. The results of the latest study were published in the American Society of Hematology's Blood journal on May 22, 2024. The researchers acknowledge that more extensive studies are necessary to confirm the broader applicability of these findings and to assess the clinical impact of earlier diagnosis and treatment. TetRS is now clinically available across the Mass General Brigham network, with the Mass General Brigham Pathology department processing samples from MGH, Brigham and Women’s Hospital, and other locations across the U.S.

“By working together across pathology, neuro-oncology and neurosurgery teams, we’ve developed an innovative, collaborative way to improve patient care,” said co-author Deborah Forst, MD, of the Mass General Cancer Center. “The ability to rapidly detect tumor-related molecular variants in patients’ spinal fluid samples has allowed us to promptly draw diagnostic conclusions through less invasive testing and to initiate individualized and potentially life-saving chemotherapies in rapid fashion.” 

Related Links:
Mass General Brigham


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more

Pathology

view channel
Image: A tool uses artificial intelligence and high-resolution imaging to track senescent cells (Courtesy of Adobe Stock)

AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease

Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.